Procter & Gamble Health Ltd - 500126 - Shareholder Meeting / Postal Ballot-Scrutinizer''s Report
We are enclosing herewith following documents: 1. Proceedings of the Postal Ballot 2. Voting results in respect of the Postal Ballot process, as required under Regulation 44 of the SEBI (Listing Obligations & Disclosure Requirements), Regulations, 2015; and 3. Scrutinizers Report Kindly take the above on record and oblige. Procter & Gamble Health Ltd - 500126 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
We have been informed by our Registrars and Share Transfer Agents (RTA), KFin Technologies Limited on May 11,2023, regarding the loss /misplacement of the share certificate(s) We request you to take the same on record and acknowledge receipt. Procter & Gamble Health Ltd - 500126 - Shareholders' Approval- Appointment Of Mr. Lokesh Chandak (DIN 10083315) As An Executive Director Of The Company For A Period Of Five Years, Effective April 1, 2023 And Appointment Of Ms. Seema Sambasivan (DIN 10085866) As A Non-Executive Director Of The Company, Effective April 1, 2023.
This has reference to our letter dated March 17,2023 with respect to: 1) Appointment of Mr. Lokesh Chandak (DIN 10083315) as an Executive Director of the Company for a period of five years, effective April 1, 2023, subject to the approval of the Shareholders of the Company; and 2) Appointment of Ms. Seema Sambasivan (DIN 10085866) as a Non-Executive Director of the Company, effective April 1, 2023, subject to the approval of the Shareholders of the Company. We are pleased to inform you that the Shareholders' have, on May 10, 2023 approved such appointments via Postal Ballot held by the Company, results of which have been declared today. Procter & Gamble Health Ltd - 500126 - Disclosure Of Voting Results Of The Postal Ballot Process
We are enclosing herewith following documents: 1. Proceedings of the Postal Ballot 2. Voting results in respect of the Postal Ballot process, as required under Regulation 44 of the SEBI (Listing Obligations & Disclosure Requirements), Regulations, 2015; and 3. Scrutinizers Report Kindly take the above on record and oblige. Procter & Gamble Health Ltd - 500126 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
We have been informed by our Registrars and Share Transfer Agents (RTA), KFin Technologies Limited on April 26,2023, regarding the loss /misplacement of the share certificate(s).
Glenmark to pay $87.5 million to settle lawsuits over a product in US
Three plaintiff groups collectively representing all of the claims against the company and Merck are referred to as the Direct Purchaser Plaintiffs, the Retailer Plaintiffs, and the End-Payor Plaintif Procter & Gamble Health Ltd - 500126 - Board Meeting Intimation for Consideration And Approval Of The Unaudited Financial Results For The Quarter Ended March 31,2023.
Procter & Gamble Health Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 15/05/2023 ,inter alia, to consider and approve In terms of Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015, we wish to inform you that a meeting of the Board of Directors of the Company is scheduled to be held on Monday, May 15,2023, inter alia, to consider and approve the unaudited financial results for the quarter ended March 31,2023. Procter & Gamble Health Ltd - 500126 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
With reference to above captioned subject, on the basis of confirmation received from our Registrar and Transfer Agent, Kfin Technologies Limited ( formerly known as Kfin Technologies Private Limited), we confirm that the details of securities dematerialised during the quarter ended March 31,2023 as required under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018, have been furnished to the stock exchanges where the shares of the Company are listed within the prescribed time period.
Pharma giant Merck acquires Prometheus for nearly $11 billion: Report
Prometheus's share price was at $114.01 when the New York Stock Exchange closed on April 14. Procter & Gamble Health Ltd - 500126 - Shareholder Meeting / Postal Ballot-Notice of Postal Ballot
We would like to submit the notice of the Postal Ballot along with Postal Ballot form with respect to the Company's proposal for seeking approval of the Members for the following items of business: 1) Appointment of Mr. Lokesh Chandak (DIN 10083315) as an Executive Director of the Company for a period of five years, effective April 1, 2023, liable to retire by rotation (Ordinary Resolution) 2) Appointment of Ms. Seema Sambasivan (DIN 10085866) as a Non-Executive Director of the Company, effective April 1, 2023, liable to retire by rotation. (Ordinary Resolution) Kindly take the above on record and acknowledge the receipt.